title: Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
abstract: A double-blind study of 42 psychotic patients treated with neuroleptics evaluated the need for prophylactic use of antiparkinsonian medication. The patients assigned to placebo (N = 27) presented significantly more severe extrapyramidal symptomatology, particularly dystonias, than those given trihexyphenidyl (N = 15), indicating a need for the prophylactic use of antiparkinsonian medication during treatment with neuroleptics.
authors.forename: N
authors.initials: N
authors.lastname: Manos
authors.forename: G
authors.initials: G
authors.lastname: Lavrentiadis
authors.forename: J
authors.initials: J
authors.lastname: Gkiouzepas
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004421:Dystonia / Q000139:chemically induced / Q000517:prevention & control; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D010043:Outcome and Process Assessment, Health Care; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control*; D010919:Placebos; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010919:Placebos